Sacituzumab govitecan ,Trodelvy ,TROP-2 ,IMMU-132 ,Oncology ADC / Triple-negative breast cancer ADC / Urothelial cancer ADC ,CAS No.1491917-83-9
Sacituzumab govitecan ,Trodelvy ,TROP-2 ,IMMU-132 ,Oncology ADC / Triple-negative breast cancer ADC / Urothelial cancer ADC ,CAS No.1491917-83-9
Trade Name
Trodelvy
Target
TROP-2
Molecular Type
ADC
Sales In 2025 (Millions Of USD)
1014(First Three Quarters)
Product Description
Detailed Specifications & Features
Trade Name : Trodelvy
Target : TROP-2
Molecular Type : ADC
Sales in 2025 (Millions of USD) : 1014(First three quarters)
All detailed product information shall be subject to the issued final COA.
Should you need further in-depth documentation for this item, kindly get in touch with us.
